Skip to main content

Table 2 Baseline characteristics of sJIA for the full analysis population

From: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement

  MRA
  2 mg/kg (n = 4) 4 mg/kg (n = 6) 8 mg/kg (n = 5) Overall (n = 15)
VAS of disease activitya (mm)     
   Mean ± SD 60.3 ± 29.94 50.5 ± 22.10 35.3 ± 30.09 48.9 ± 26.49
   Range 20, 92 17, 74 11, 73f 11, 92g
VAS of overall well-beinga (mm)     
   Mean ± SD 42.8 ± 29.28 56.5 ± 34.85 59.2 ± 10.57 53.7 ± 26.42
   Range 5,76 20, 100 50, 75 5, 100
Total number of active jointsb     
   Mean ± SD 27.8 ± 9.54 23.2 ± 13.01 12.4 ± 13.15 20.8 ± 13.07
   Range 15, 36 4, 38 4, 35 4, 38
Total number of joints with limitation of movementb     
   Mean ± SD 17.8 ± 10.28 15.2 ± 11.27 12.8 ± 13.10 15.1 ± 11.00
   Range 7, 30 5, 35 5, 36 5, 36
ESR (mm/h)     
   Mean ± SD 114.3 ± 20.45 78.0 ± 25.85 60.0 ± 18.13f 83.2 ± 30.07g
   Range 95, 140 30, 100 35, 78 30, 140
CRP (mg/l)     
   Mean ± SD 140.8 ± 90.08 119.0 ± 52.23 125.6 ± 39.48 NC
   Range 59, 262 60, 189 89, 178  
Functional abilityc     
   Mean ± SD 0.7 ± 0.68 1.2 ± 0.89 2.3 ± 0.36 1.4 ± 0.91
   Range 0.03, 1.5 0.13, 2.38 1.75, 2.75 0.03, 2.75
Total Systemic Feature Scored     
   Mean ± SD 3.0 ± 1.41 3.2 ± 1.72 3.0 ± 2.45 3.1 ± 1.79
   Range 2, 5 1, 6 0, 6 0, 6
  1. aMeasured on an increasing scale of 0 to 100 mm. bMaximum of 81. cCHAQ: maximum of 3. dMaximum of 8. eN = 2;individual patient's data presented. fN = 4. gN = 14. CHAQ, childhood health assessment questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NC, not calculated; SD, standard deviation; VAS, visual analogue scale.